Refine your search
Collections
Co-Authors
Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Verma, Nikhil
- Evaluation of the Relative Efficacy and Safety of Prasugrel and Clopidogrel in Medically Managed High Risk UA/NSTEMI ACS Population
Abstract Views :275 |
PDF Views:140
Authors
Affiliations
1 Department of medicine, Unit-5, Guru Nanak Dev Hospital, Amritsar, Punjab, IN
1 Department of medicine, Unit-5, Guru Nanak Dev Hospital, Amritsar, Punjab, IN
Source
International Journal of Medical and Dental Sciences, Vol 4, No 2 (2015), Pagination: 809-817Abstract
Background: The term "acute coronary syndrome" encompasses unstable angina and non-ST-segment elevation myocardial infarction (UA/NSTEMI) and ST-segment elevation myocardial infarction (STEMI). Antiplatelet therapy is one of the cornerstones of therapy in UA/NSTEMI.
Objective: To compare efficacy and safety of Prasugrel and clopidogrel both theinopyridines antiplatelet drugs in high risk (TIMI Score 3 or more) medically managed UA/NSTEMI.
Materials and Methods: A prospective, randomized study was conducted in GNDH, Amritsar. 100 patients were included, 50 patients received Prasugrel and 50 received clopidogrel. Outcomes like angina episodes, bleeding, stroke, ischemic ECG changes, and arrhythmia were compared during hospital stay and follow-up for 3 months.
Results: Prasugrel was associated with significant lower incidence of major adverse cardiac event (MACE) 9 compared to 19 with clopidogrel during hospital stay. During follow up for 3 months 2 events occurred with Prasugrel and 3 with clopidogrel which were non-significant.
Conclusion: Use of Prasugrel was associated with less number of MACE than the patients who were on clopidogrel. Although for the individual adverse coronary events, except for angina there was no statically significant difference, but when the total MACE observed during the study was compared, it was significantly less in the patient on Prasugrel therapy. Safety of the Prasugrel in present study was identical to clopidogrel.
Keywords
1. Braunwald E, Antman EM, Beasley JW. ACC/AHA guideline update for the management of patients with unstable angina and non-ST segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task force on practice Guidelines (Committee on the management of patients with unstable angina). Circulation 2002;106:1893-900. 2. Fuster V, Badimon L, Badimon JJ. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;326:242-50. 3. Patrono C. Drug therapy: aspirin as an antiplatelet agent. N Engl J Med 1994;330:1287-94. 4. Antiplatelet Trialists Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. Prevention of death, myocardial infarction, and strokeUnstable Angina, Non ST Elevation Myocardial Infarction, Prasugrel, Clopidogrel.Full Text
References
- Braunwald E, Antman EM, Beasley JW. ACC/AHA guideline update for the management of patients with unstable angina and non-ST segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task force on practice Guidelines (Committee on the management of patients with unstable angina). Circulation 2002;106:1893-900.
- Fuster V, Badimon L, Badimon JJ. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;326:242-50.
- Patrono C. Drug therapy: aspirin as an antiplatelet agent. N Engl J Med 1994;330:1287-94.
- Antiplatelet Trialists Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994;308:81-106.
- Gachet C. Regulation of platelet functions by P2 receptors. Annu Rev Pharmacol Toxicol 2006;46:277–300.
- Gachet C. P2 receptors, platelet function and pharmacological implications. Thromb Haemost 2008;99(3):466–72.
- Gachet C. ADP receptors of platelets and their inhibition. Thromb Haemost. 2001;86(1):222–32.
- Savi P, Pereillo JM and Uzabiaga MF. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost. 2000;84(5):891–6.
- Kaushansky K. Thrombopoietin. N Engl J Med 1998;339:746–754.
- Cattaneo M, Winocour PD, Somers DA, Groves HM, Kinlough-Rathbone RL, Packham MA, Mustard JF. Effect of ticlopidine on platelet aggregation, adherence to damaged vessels, thrombus formation and platelet survival. Thromb Res 1985;37:29–43.
- Lins R, Broekhuysen J, Necciari J, Deroubaix X. Pharmacokinetic profile of 14C-labeled clopidogrel. Semin Thromb Hemost 1999;25(2):29–33.
- Kurihara HK, Kazui M, Ishizuka T, Farid NA and Ikeda T. In vitro metabolism of antiplatelet agent clopidogrel: cytochrome P450 isoforms responsible for two oxidation steps involved in active metabolite formation. Drug Metab Rev 2005;37(2):99.
- The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494502.
- Chen ZM, Jiang LX, Chen YP. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1607-21.
- Sabatine MS, Cannon CP, Gibson CM. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352:1179-89.
- Mehta SR, Yusuf S. Short and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention. J Am Coll Cardiol 2003;41:Suppl S:79-88.
- Steinhubl SR, Berger PB, Mann JT. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-20.
- A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996;348: 1329–1339.
- Xiao Z, Theroux P. Clopidogrel inhibits platelet–leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome. J Am Coll Cardiol 2004;43:1982–1988.
- Quinn MJ, Bhatt DL, Zidar F, Vivekananthan D, Chew DP, Ellis SG, et al. Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention. Am J Cardiol 2004;93:679–684.
- Vivekananthan DP, Bhatt DL, Chew DP, Zidar FJ, Chan AW, Moliterno DJ et al. Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention. Am J Cardiol 2004;94:358–360.
- Gurbel PA, Bliden KP. Durability of platelet inhibition by clopidogrel. Am J Cardiol 2003;91:1123-5.
- Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ.Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005;45:246-51.
- Buonamici P, Marcucci R, Migliorini A. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007;49:2312-7.
- Gurbel PA, Bliden KP, Samara W. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol 2005;46:1827-32.
- Hochholzer W, Trenk D, Bestehorn HP. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006;48:1742-50.
- Matetzky S, Shenkman B, Guetta V. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109:3171-5.
- Wallentin L. P2Y (12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J 2009;30:1964–77.
- Michelson AD. New P2Y12 antagonists. Curr Opin Hematol 2009;16:371–7.
- Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA, Ernest CS et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 2007;5:2429–36.
- Jakubowski JA, Payne CD, Brandt JT. The platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy subjects. J Cardiovasc Pharmacol 2006;47:377-84.
- Wiviott SD, Braunwald E, McCabe HC. Prasugrel versus Clopidogrel in patients with Acute Coronary Syndromes. N Engl J Med 2007;357:2001-5.
- Wiviott SD, Dietmer T, Frelinger AL. Maintenance-Dose Clopidogrel in patients with Planned Percutaneous Coronary Intervention: The Prasugrel in Comparison to Clopidogrel for inhibition of Platelet activation and Aggregation-Thrombolysis in Myocardial Infarction 44 Trial. Circulation 2007;116:2923-32.
- Wiviott SD, Antman ME, Winters KJ. Randomized Comparison on Prasugrel (CS-747, LY640315), a Novel Theinopyridines P2y12 Antagonist, With Clopidogrel in Percutaneous Coronary Intervention: Results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 Trial. Circulation 2005;111:3366-73.
- Huges LO, Raval U, Raftery EB. First myocardial infarctions in Asian and white men. Br Med J 1989;298:1345-50.
- Enas EA, Dhawan J, Petkar S. Coronary artery disease in Asian Indians: lessons learnt and the role of lipoprotein-a. Indian Heart J 1996;49:25-34.
- Yusuf S, Hawken S, Ounpuu S. Effects of potentially modifiable risk factors associated with myocardial infarction in 52 countries (The INTERHEART study): case control study. Lancet 2004;364:937-52.